Myriad Genetics (MYGN) Misses Q1 EPS by 24c; Lowers Outlook
Myriad Genetics (NASDAQ: MYGN) reported Q1 EPS of $0.08, $0.24 worse than the analyst estimate of $0.32. Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)